Your browser is no longer supported. Please, upgrade your browser.
Settings
BMY Bristol-Myers Squibb Company daily Stock Chart
BMY [NYSE]
Bristol-Myers Squibb Company
IndexS&P 500 P/E- EPS (ttm)-0.11 Insider Own0.10% Shs Outstand2.26B Perf Week1.55%
Market Cap142.00B Forward P/E8.46 EPS next Y7.46 Insider Trans-10.57% Shs Float2.23B Perf Month9.16%
Income-44.00M PEG- EPS next Q1.41 Inst Own75.80% Short Float0.72% Perf Quarter1.09%
Sales39.40B P/S3.60 EPS this Y-33.90% Inst Trans-0.11% Short Ratio1.52 Perf Half Y4.58%
Book/sh22.22 P/B2.84 EPS next Y16.78% ROA0.00% Target Price74.06 Perf Year9.46%
Cash/sh9.39 P/C6.71 EPS next 5Y21.35% ROE-0.10% 52W Range45.76 - 68.34 Perf YTD-1.78%
Dividend1.80 P/FCF17.80 EPS past 5Y10.90% ROI5.50% 52W High-7.74% Beta0.65
Dividend %2.85% Quick Ratio1.60 Sales past 5Y10.50% Gross Margin71.50% 52W Low37.78% ATR1.44
Employees30000 Current Ratio1.70 Sales Q/Q75.50% Oper. Margin8.70% RSI (14)54.24 Volatility1.81% 2.32%
OptionableYes Debt/Eq0.90 EPS Q/Q-1.30% Profit Margin-0.10% Rel Volume0.39 Prev Close62.84
ShortableYes LT Debt/Eq0.82 EarningsNov 05 BMO Payout- Avg Volume10.60M Price63.05
Recom1.90 SMA200.80% SMA503.49% SMA2005.34% Volume4,176,597 Change0.33%
Nov-16-20Upgrade Societe Generale Hold → Buy $76
Nov-10-20Resumed Bernstein Mkt Perform
Nov-06-20Downgrade Gabelli & Co Buy → Hold
Oct-19-20Upgrade Guggenheim Neutral → Buy $70
Sep-29-20Initiated Berenberg Buy $73
Jul-28-20Initiated Raymond James Outperform $75
Apr-02-20Upgrade Morgan Stanley Equal-Weight → Overweight $64
Mar-23-20Downgrade Societe Generale Buy → Hold $50
Feb-27-20Initiated Barclays Equal Weight $69
Jan-06-20Resumed Citigroup Buy $73
Dec-13-19Upgrade Argus Hold → Buy $80
Nov-22-19Resumed Morgan Stanley Equal-Weight $60
Oct-17-19Resumed BofA/Merrill Buy $60
Aug-14-19Upgrade Atlantic Equities Neutral → Overweight $63
May-28-19Initiated Goldman Buy
May-20-19Downgrade Argus Buy → Hold
May-03-19Upgrade Barclays Equal Weight → Overweight $53 → $55
May-03-19Resumed JP Morgan Overweight $62
Jan-15-19Upgrade Societe Generale Sell → Buy
Oct-22-18Downgrade Citigroup Buy → Neutral
Nov-25-20 01:14PM  
Nov-24-20 02:54PM  
06:59AM  
06:15AM  
Nov-23-20 11:33AM  
10:33AM  
07:01AM  
06:30AM  
Nov-19-20 04:36PM  
Nov-18-20 12:24PM  
06:08AM  
01:29AM  
Nov-17-20 03:39PM  
12:43PM  
11:12AM  
09:45AM  
08:30AM  
06:59AM  
01:42AM  
Nov-16-20 07:56PM  
06:54PM  
05:34PM  
05:30PM  
04:38PM  
04:30PM  
04:21PM  
01:54PM  
Nov-13-20 03:22PM  
Nov-12-20 07:15AM  
Nov-11-20 04:15PM  
06:59AM  
Nov-10-20 12:35PM  
Nov-09-20 07:27PM  
05:05PM  
11:29AM  
10:03AM  
06:59AM  
Nov-08-20 07:24AM  
Nov-06-20 08:15PM  
11:20AM  
10:33AM  
06:59AM  
02:31AM  
01:31AM  
Nov-05-20 04:08PM  
02:00PM  
11:17AM  
10:41AM  
10:41AM  
10:00AM  
09:43AM  
08:25AM  
08:22AM  
07:25AM  
07:01AM  
06:59AM  
06:59AM  
Nov-04-20 08:32AM  
06:59AM  
06:01AM  
Nov-03-20 04:14PM  
02:03PM  
10:48AM  
09:46AM  
07:38AM  
06:59AM  
06:59AM  
Nov-02-20 11:58AM  
05:50AM  
Nov-01-20 02:33AM  
Oct-31-20 08:22AM  
Oct-30-20 10:49AM  
Oct-29-20 02:12PM  
12:35PM  
06:14AM  
06:05AM  
Oct-28-20 04:48PM  
12:47PM  
12:30PM  
Oct-27-20 08:45AM  
07:05AM  
Oct-26-20 05:45PM  
02:47PM  
08:00AM  
05:51AM  
Oct-24-20 07:30AM  
Oct-23-20 10:05AM  
07:11AM  
Oct-22-20 10:15AM  
Oct-21-20 10:48AM  
Oct-19-20 05:25PM  
05:21PM  
04:27PM  
03:24PM  
12:06PM  
11:55AM  
11:47AM  
09:50AM  
06:59AM  
06:06AM  
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products in hematology, oncology, cardiovascular, and immunology therapeutic classes. The company's products include Opdivo for anti-cancer indications; Eliquis, an oral inhibitor targeted at stroke prevention in adult patients with non-valvular atrial fibrillation, and the prevention and treatment of venous thromboembolic disorders; and Orencia for adult patients with active RA and prostate-specific antigen, as well as reducing signs and symptoms in pediatric patients with active polyarticular juvenile idiopathic arthritis. It also provides Sprycel, a tyrosine kinase inhibitor for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy, a monoclonal antibody for the treatment of patients with unresectable or metastatic melanoma; Empliciti, a humanized monoclonal antibody for the treatment of multiple myeloma; and Baraclude, an oral antiviral agent for the treatment of chronic hepatitis B. In addition, it offers Reyataz, a protease inhibitor to treat human immunodeficiency virus (HIV); Sustiva franchise, a non-nucleoside reverse transcriptase inhibitor for the treatment of HIV; and Daklinza NS5A replication complex inhibitor, Sunvepra NS3 protease inhibitor, and Beclabuvir NS5B inhibitor. It sells products to wholesalers, retail pharmacies, hospitals, government entities, and medical profession. The company has collaboration agreements with Pfizer, Otsuka, Ono, Nektar, GRYT Health, Ubiquigent Limited, and Sensyne Health plc; clinical collaboration with NeoImmuneTech, Inc.; partnership with Astrazeneca Plc; a discovery collaboration with Insitro, Inc.; and collaboration with Schrodinger, Inc. The company was formerly known as Bristol-Myers Company and changed its name to Bristol-Myers Squibb Company in 1989. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in New York, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
von Autenried PaulEVP, Chief Information OfficerNov 24Sale62.7520,0001,255,000126,701Nov 25 04:31 PM
Dubow AdamSVP,ChiefCompliance&EthicsOff.Nov 24Sale63.3990057,05115,186Nov 25 04:32 PM
VESSEY RUPERTEVP, Research & Early Dev.Nov 23Sale61.3413,421823,24437,922Nov 25 04:32 PM
VESSEY RUPERTEVP, Research & Early Dev.Nov 19Option Exercise49.2852,2132,572,88798,355Nov 23 05:40 PM
VESSEY RUPERTEVP, Research & Early Dev.Nov 19Sale61.3057,5913,530,26946,142Nov 23 05:40 PM
AHMED NADIMEVP and President, HematologyOct 30Option Exercise0.004,650030,680Nov 03 04:28 PM
VESSEY RUPERTEVP, Research & Early Dev.Oct 30Option Exercise0.005,804059,580Nov 03 04:27 PM
Santiago Karen MurphySVP & ControllerSep 01Option Exercise0.0064208,390Sep 02 04:33 PM
Caforio GiovanniChairman and CEOAug 31Sale62.7039,8402,497,968445,584Sep 02 04:34 PM
Eid JosephSVP,Head Glob. Medical AffairsAug 17Sale64.005,327340,9282,534Aug 19 06:15 PM
LEUNG SANDRAEVP, General CounselAug 13Sale63.24141,4208,943,401432,744Aug 17 04:55 PM
Elkins David VEVP, Chief Financial OfficerAug 01Option Exercise0.0046,402080,698Aug 04 04:43 PM
Hirawat SamitEVP,Chief Med.Offr.,Drug Dev.Jul 01Option Exercise0.009,35609,356Jul 02 04:56 PM
Santiago Karen MurphySVP & ControllerJul 01Option Exercise0.001,06908,115Jul 02 04:54 PM
Paliwal Dinesh CDirectorJun 15Buy54.509,174499,98322,109Jun 16 05:15 PM
Haller Julia ADirectorJun 14Option Exercise0.0055806,819Jun 16 05:15 PM
BONNEY MICHAEL WDirectorJun 14Option Exercise0.0055808,650Jun 16 05:16 PM
Haller Julia ADirectorJun 13Option Exercise0.0090306,261Jun 16 05:15 PM
BONNEY MICHAEL WDirectorJun 13Option Exercise0.0090308,092Jun 16 05:16 PM
Eid JosephSVP,Head Glob. Medical AffairsJun 03Option Exercise0.002,15408,599Jun 09 07:15 PM
Haller Julia ADirectorJun 03Option Exercise0.002,94905,358Jun 05 04:39 PM
BONNEY MICHAEL WDirectorJun 03Option Exercise0.002,94907,189Jun 05 04:40 PM
Dubow AdamSVP,ChiefCompliance&EthicsOff.May 22Sale61.013,200195,23216,086May 26 05:17 PM
Schmukler Louis SEVP,Pres.,Glob.Prod. & SupplyMay 19Sale62.6825,0001,567,00026,777May 21 05:22 PM
VESSEY RUPERTEVP, Research & Early Dev.May 01Option Exercise0.0010,707059,050May 05 04:49 PM
AHMED NADIMEVP and President, HematologyMay 01Option Exercise0.002,908027,463May 05 04:49 PM
Schmukler Louis SEVP,Pres.,Glob.Prod. & SupplyMar 10Option Exercise0.0030,519058,379Mar 12 06:18 PM
von Autenried PaulEVP, Chief Information OfficerMar 10Option Exercise0.0020,8060152,400Mar 12 06:19 PM
Powell AnnEVP, Chief Human ResourcesMar 10Option Exercise0.0031,169058,421Mar 12 06:17 PM
Santiago Karen MurphyControllerMar 10Option Exercise0.005,06307,778Mar 12 06:17 PM
LEUNG SANDRAEVP, General CounselMar 10Option Exercise0.0051,5980588,175Mar 12 06:15 PM
Eid JosephSVP,Head Glob. Medical AffairsMar 10Option Exercise0.001,57106,652Mar 12 06:13 PM
Elicker John EEVP, Investor RelationsMar 10Option Exercise0.0018,407075,102Mar 12 06:14 PM
Caforio GiovanniChairman and CEOMar 10Option Exercise0.00211,7960544,032Mar 12 06:11 PM
Dubow AdamSVP,ChiefCompliance&EthicsOff.Mar 10Option Exercise0.005,007020,091Mar 12 06:12 PM
Bancroft Charles AEVP, Head of IntegrationMar 10Option Exercise0.0071,8680153,637Mar 12 06:11 PM
BOERNER CHRISTOPHER S.EVP, Chief Commercial OfficerMar 10Option Exercise0.0021,426026,091Mar 12 06:11 PM
Elicker John EEVP, Investor RelationsMar 04Sale61.0115,805964,26358,666Mar 06 05:20 PM
VESSEY RUPERTPres., Research & Early Dev.Mar 02Option Exercise51.6993,4684,831,452132,651Mar 04 06:19 PM
VESSEY RUPERTPres., Research & Early Dev.Mar 02Sale60.5984,3085,108,22248,343Mar 04 06:19 PM
AHMED NADIMPresident, HematologyMar 01Option Exercise0.0017,204033,028Mar 03 08:04 PM
Elkins David VEVP, Chief Financial OfficerMar 01Option Exercise0.0024,579044,766Mar 03 08:04 PM
VESSEY RUPERTPres., Research & Early Dev.Mar 01Option Exercise0.0023,349048,106Mar 03 08:05 PM
AHMED NADIMPresident, HematologyFeb 04Option Exercise0.002,076016,895Feb 06 08:48 PM
VESSEY RUPERTPres., Research & Early Dev.Feb 04Option Exercise0.003,592025,920Feb 06 08:49 PM
Elkins David VEVP, Chief Financial OfficerDec 31Option Exercise0.0012,373026,281Jan 03 07:00 PM
VESSEY RUPERTPres., Research & Early Dev.Dec 31Option Exercise0.0016,060030,778Jan 03 07:00 PM
Dubow AdamChief Compliance & Ethics OffiDec 05Sale58.811,740102,32915,749Dec 09 04:44 PM
BONNEY MICHAEL WDirectorDec 04Buy58.90885,1837,189Jun 09 07:16 PM
Eid JosephSVPHead Global Medical AffairsDec 01Option Exercise0.002,82504,995Dec 03 05:28 PM